Literature DB >> 23666510

Immune-suppressive properties of the tumor microenvironment.

Jürgen C Becker1, Mads Hald Andersen, David Schrama, Per Thor Straten.   

Abstract

Solid tumors are more than an accumulation of cancer cells. Indeed, cancerous cells create a permissive microenvironment by exploiting non-transformed host cells. Thus, solid tumors rather resemble abnormal organs composed of the cancerous cells itself and the stroma providing the supportive framework. The stroma can be divided into the extracellular matrix consisting of proteoglycans, hyaluronic acid, and fibrous proteins, as well as stromal cells including mesenchymal and immune cells; moreover, it contains various peptide factors and metabolites. Here, we will focus on immune-modulating capacities of the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666510     DOI: 10.1007/s00262-013-1434-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  77 in total

Review 1.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

2.  Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.

Authors:  Alexander L Rakhmilevich; Mildred Felder; Lauren Lever; Jacob Slowinski; Kayla Rasmussen; Anna Hoefges; Tyler J Van De Voort; Hans Loibner; Alan J Korman; Stephen D Gillies; Paul M Sondel
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

Review 3.  Metabolism of stromal and immune cells in health and disease.

Authors:  Bart Ghesquière; Brian W Wong; Anna Kuchnio; Peter Carmeliet
Journal:  Nature       Date:  2014-07-10       Impact factor: 49.962

4.  Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Authors:  Chris G Twitty; Oscar R Diago; Daniel J Hogan; Cindy Burrascano; Carlos E Ibanez; Douglas J Jolly; Derek Ostertag
Journal:  Hum Gene Ther Methods       Date:  2015-12-01       Impact factor: 2.396

Review 5.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 6.  Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Authors:  Jürgen C Becker; Andreas Stang; Axel Zur Hausen; Nicole Fischer; James A DeCaprio; Richard W Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K Bichakjian; Selma Ugurel; David Schrama
Journal:  Cancer Immunol Immunother       Date:  2017-11-30       Impact factor: 6.968

Review 7.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

8.  T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.

Authors:  Rikke Lyngaa; Natasja Wulff Pedersen; David Schrama; Charlotte Albæk Thrue; Dafina Ibrani; Ozcan Met; Per Thor Straten; Paul Nghiem; Jürgen C Becker; Sine Reker Hadrup
Journal:  Clin Cancer Res       Date:  2014-02-13       Impact factor: 12.531

Review 9.  Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.

Authors:  Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2014-08       Impact factor: 11.151

Review 10.  Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.

Authors:  S Chouaib; M Z Noman; K Kosmatopoulos; M A Curran
Journal:  Oncogene       Date:  2016-06-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.